Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Haemo-autologous Antegrade Repriming (HAR) Clinical Trial for Validation as Minimum Impact Perfusion Strategy in Cardiopulmonary Bypass

NCT03720184 is registered in ClinicalTrials.gov with Juan Blanco Morillo as lead sponsor.

NCT NCT03720184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03720184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Haemo-autologous Antegrade Repriming (HAR) Clinical Trial for Validation as Minimum Impact Perfusion Strategy in Cardiopulmonary Bypass
Lead sponsor
Juan Blanco Morillo
Phase
Not applicable
Overall status
Completed
Start date
August 15, 2018
Completion date
February 9, 2021
Enrollment
116 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, cardiac disease, cognitive; disorder, due to general medical condition, embolism, air, extracorporeal circulation; complications, transfusion, valve anomalies